REGN Regeneron Stock Outlook 2026: Dupixent's Momentum vs. Eylea's Biosimilar Reckoning
REGN Regeneron stock outlook 2026. Dupixent global sales hit $4.9B in Q1 2026 (+33%), Eylea HD biosimilar transition, Lynozyfic FDA approval July 2025, Libtayo oncology surge, three-scenario valuation for US investors.
REGN Regeneron Dupixent